These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31079266)

  • 1. PCSK9 and Lp(a) levels of children born after assisted reproduction technologies.
    Vlachopoulos C; Kosteria I; Sakka S; Gkourogianni A; Terentes-Printzios D; Koutagiar I; Skoumas I; Miliou A; Papassotiriou I; Gardikioti V; Loutradis D; Chrousos G; Kanaka-Gantenbein C; Tousoulis D
    J Assist Reprod Genet; 2019 Jun; 36(6):1091-1099. PubMed ID: 31079266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
    J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
    Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International collaborative study of intracytoplasmic sperm injection-conceived, in vitro fertilization-conceived, and naturally conceived 5-year-old child outcomes: cognitive and motor assessments.
    Ponjaert-Kristoffersen I; Bonduelle M; Barnes J; Nekkebroeck J; Loft A; Wennerholm UB; Tarlatzis BC; Peters C; Hagberg BS; Berner A; Sutcliffe AG
    Pediatrics; 2005 Mar; 115(3):e283-9. PubMed ID: 15741353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
    Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N;
    J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
    Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 Association With Lipoprotein(a).
    Tavori H; Christian D; Minnier J; Plubell D; Shapiro MD; Yeang C; Giunzioni I; Croyal M; Duell PB; Lambert G; Tsimikas S; Fazio S
    Circ Res; 2016 Jun; 119(1):29-35. PubMed ID: 27121620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and metabolic profiles of offspring conceived by assisted reproductive technologies: a systematic review and meta-analysis.
    Guo XY; Liu XM; Jin L; Wang TT; Ullah K; Sheng JZ; Huang HF
    Fertil Steril; 2017 Mar; 107(3):622-631.e5. PubMed ID: 28104241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
    Ridker PM; Rifai N; Bradwin G; Rose L
    Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction.
    Nakamura A; Kanazawa M; Kagaya Y; Kondo M; Sato K; Endo H; Nozaki E
    J Cardiol; 2020 Oct; 76(4):395-401. PubMed ID: 32439340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.
    Yang SH; Li S; Zhang Y; Xu RX; Zhu CG; Guo YL; Wu NQ; Qing P; Gao Y; Cui CJ; Dong Q; Sun J; Li JJ
    J Endocrinol Invest; 2016 Aug; 39(8):875-83. PubMed ID: 26894681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum insulin-like growth factor-I (IGF-I) and growth in children born after assisted reproduction.
    Kai CM; Main KM; Andersen AN; Loft A; Chellakooty M; Skakkebaek NE; Juul A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4352-60. PubMed ID: 16912121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mental health and developmental outcomes for children born after ART: a comparative prospective study on child gender and treatment type.
    Punamäki RL; Tiitinen A; Lindblom J; Unkila-Kallio L; Flykt M; Vänskä M; Poikkeus P; Tulppala M
    Hum Reprod; 2016 Jan; 31(1):100-7. PubMed ID: 26516205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do the children born after assisted reproductive technology have an increased risk of birth defects? A systematic review and meta-analysis.
    Zhao J; Yan Y; Huang X; Li Y
    J Matern Fetal Neonatal Med; 2020 Jan; 33(2):322-333. PubMed ID: 30189770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.